Advertisement

Current Hypertension Reports

, 20:81 | Cite as

The Effects of Oral Taurine on Resting Blood Pressure in Humans: a Meta-Analysis

  • Mark Waldron
  • Stephen David Patterson
  • Jamie Tallent
  • Owen Jeffries
Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Antihypertensive Agents: Mechanisms of Drug Action

Abstract

Purpose of Review

The aims of this meta-analysis were to investigate the effects of orally administered isolated taurine on resting systolic blood pressure (SBP) and diastolic blood pressure (DBP) in humans.

Recent Findings

There is growing evidence that taurine deficiency is associated with hypertension and that oral supplementation can have antihypertensive effects in humans. However, these investigations have been conducted across a number of decades and populations and have not been collectively reviewed. A search was performed using various databases in May 2018 and later screened using search criteria for eligibility. There were seven peer-reviewed studies meeting the inclusion criteria, encompassing 103 participants of varying age and health statuses. Taurine ingestion reduced SBP (Hedges’ g = − 0.70, 95% CI − 0.98 to − 0.41, P < 0.0001) and DBP (Hedges’ g = − 0.62, 95% CI − 0.91 to − 0.34, P < 0.0001). These results translated to mean ~ 3 mmHg reductions in both SBP (range = 0–15 mmHg) and DBP (range = 0–7 mmHg) following a range of doses (1 to 6 g/day) and supplementation periods (1 day to 12 weeks), with no adverse events reported.

Summary

These preliminary findings suggest that ingestion of taurine at the stated doses and supplementation periods can reduce blood pressure to a clinically relevant magnitude, without any adverse side effects. Future studies are needed to establish the effects of oral taurine supplementation on targeted pathologies and the optimal supplementation doses and periods.

Keywords

Hypertension Taurine deficiency Oral taurine 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of major Importance

  1. 1.
    WHO Raised blood pressure: situation and trends. Global Health Observatory. http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/ (accessed 04 May 2018).
  2. 2.
    Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJL. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347–60.CrossRefPubMedGoogle Scholar
  3. 3.
    Smith SC, Benjamin EJ, Bonow RO, et al. World Heart Federation and the Preventive Cardiovascular Nurses Association. Circulation. 2011;124:2458–73.CrossRefPubMedGoogle Scholar
  4. 4.
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC VII report. JAMA. 2003;289:2560–72.CrossRefPubMedGoogle Scholar
  5. 5.
    Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med. 1995;155:701–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47:296–308.CrossRefPubMedGoogle Scholar
  7. 7.
    COLLABORATION BPLTT. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–35.CrossRefGoogle Scholar
  8. 8.
    Savica V, Bellinghieri G, Kopple JD. The effect of nutrition on blood pressure. Annu Rev Nutr. 2010;30:365–401.CrossRefPubMedGoogle Scholar
  9. 9.
    Xu Y, Arneja AS, Tappia PS, Dhalla NS. The potential health benefits of taurine in cardiovascular disease. Exp Clin Cardiol. 2008;13:57–65.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Schaffer SW, Ito T, Azuma J. Clinical significance of taurine. Amino Acids. 2014;46:1–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Laidlaw SA, Grosvenor M, Kopple JD. The taurine content of common foodstuffs. Parenter Enter Nutr. 1990;14:183–8.CrossRefGoogle Scholar
  12. 12.
    Huxtable JR. Physiological actions of taurine. Physiol Rev. 1992;72:101–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Satoh H, Sperelakis N. Review of some actions of taurine on ion channels of cardiac muscle cells and others. Gen Pharmacol. 1998;30:451–63.CrossRefPubMedGoogle Scholar
  14. 14.
    Liao XB, Zhou XM, Li JM, Tan ZP, Liu LM, Zhang W, et al. Taurine transporter is expressed in vascular smooth muscle cells. Amino Acids. 2007;33:639–43.CrossRefPubMedGoogle Scholar
  15. 15.
    Ulusoy KG, Kaya E, Karabacak K, Seyrek M, Duvan İ, Yildirim V, et al. Taurine relaxes human radial artery through potassium channel opening action. Korean J Physiol Pharmacol. 2017;21:617–23.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yoshioka M, Takasugi Y, Koga Y. Central hypotensive effect involving neurotransmitters of long-term administration of taurine to stroke-prone spontaneously hypertensive rat. Masui. 2007;56:139–47.PubMedGoogle Scholar
  17. 17.
    Ito T, Schaffer S, Azuma J. The effect of taurine on chronic heart failure: actions of taurine against catecholamine and angiotensin II. Amino Acids. 2014;46:111–9.CrossRefPubMedGoogle Scholar
  18. 18.
    •• Sagara M, Murakami S, Mizushima S, et al. Taurine in 24-h urine samples is inversely related to cardiovascular risks of middle aged subjects in 50 populations of the world. Adv Exp Med Biol. 2015;803:623–36. This multi-centre, cross-sectional study of > 4,000 patients demonstrated an inverse relationship between 24-h urinary taurine/creatinine ratios and both hypertension and obesity, highlighting the links between taurine deficiency and cardiovascular disease risk. CrossRefPubMedGoogle Scholar
  19. 19.
    Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Higgins JP, Altman DG. Assessing risk of bias in included studies. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions: cochrane book series. Chichester: Wiley; 2008.CrossRefGoogle Scholar
  21. 21.
    Lipsey MW, Wilson DB. Practical meta-analysis. London: Sage; 2001.Google Scholar
  22. 22.
    Rosenthal R, Rosnow RL. Essentials of behavioral research: methods and data analysis. New York: McGraw-Hill; 1984.Google Scholar
  23. 23.
    Satoh H, Kang J. Modulation by taurine of human arterial stiffness and wave reflection. Adv Exp Med Biol. 2009;643:47–55.CrossRefPubMedGoogle Scholar
  24. 24.
    Mizushima S, Nara Y, Sawamura M, et al. Effects of oral taurine supplementation on lipids and sympathetic nerve tone. Adv Exp Med Biol. 1996;403:615–22.CrossRefPubMedGoogle Scholar
  25. 25.
    Ahmadian M, Roshan VD, Ashourpore E. Taurine supplementation improves functional capacity, myocardial oxygen consumption, and electrical activity in heart failure. J Diet Suppl. 2017;14:422–32.CrossRefPubMedGoogle Scholar
  26. 26.
    Beyranvand MR, Khalafi MK, Roshan VD, Choobineh S, Parsa SA, Piranfar MA. Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol. 2011;57:333–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Fujita T, Ando K, Noda H, Ito Y, Sato Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation. 1987;75:525–32.CrossRefPubMedGoogle Scholar
  28. 28.
    Warnock R, Jeffries O, Patterson S, Waldron M. The effects of caffeine, taurine or caffeine-taurine co-ingestion on repeat-sprint cycling performance and physiological responses. Int J Sports Physiol Perform. 2017;24:1–24.Google Scholar
  29. 29.
    Schwarzer R, Kivaranovic D, Mandorfer M. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Aliment Pharmacol Ther. 2018;47:86–94.CrossRefPubMedGoogle Scholar
  30. 30.
    • Sun Q, Wang B, Li Y, et al. Taurine supplementation lowers blood pressure and improves vascular function in prehypertension: randomized, double-blind, placebo-controlled study. Hypertension. 2016;67:541–9. This randomized, double-blind, placebo-controlled study demonstrated that oral taurine supplementation lowered blood pressure in a large cohort ( n = 120) of pre-hypertensive participants and provided the first mechanistic understanding of taurine’s effects on the vasculature. PubMedGoogle Scholar
  31. 31.
    Moloney MA, Casey RG, O'Donnell DH, Fitzgerald P, Thompson C, Bouchier-Hayes DJ. Two weeks taurine supplementation reverses endothelial dysfunction in young male type 1 diabetics. Diab Vasc Dis Res. 2010;7:300–10.CrossRefPubMedGoogle Scholar
  32. 32.
    Siervo M, Lara J, Ogbonmwan I, Mathers JC. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis. J Nutr. 2013;143:818–26.CrossRefPubMedGoogle Scholar
  33. 33.
    Zhao D, Liu H, Dong P. A meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension. Clin Exp Hypertens. 2018;28:1–5.Google Scholar
  34. 34.
    Liang W, Ma H, Cao L, Yan W, Yang J. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. J Cell Mol Med. 2017;21:2634–42.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Peck RN, Smart LR, Beier R, Liwa AC, Grosskurth H, Fitzgerald DW, et al. Difference in blood pressure response to ACE-inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trials. BMC Nephrol. 2013;14:201.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Shao A, Hathcock JN. Risk assessment for the amino acids taurine, L-glutamine and Larginine. Regul Toxicol Pharmacol. 2008;50:376–99.CrossRefPubMedGoogle Scholar
  37. 37.
    Ristori MT, Verdetti J. Effects of taurine on rat aorta in vitro. Fundam Clin Pharmacol. 1991;5:245–58.CrossRefPubMedGoogle Scholar
  38. 38.
    Niu LG, Zhang MS, Liu Y, Xue WX, Liu DB, Zhang J, et al. Vasorelaxant effect of taurine is diminished by tetraethylammonium in rat isolated arteries. Eur J Pharmacol. 2008;580:169–74.CrossRefPubMedGoogle Scholar
  39. 39.
    Nishida S, Satoh H. Vascular modulation of rat aorta by taurine. Adv Exp Med Biol. 2009;643:37–46.CrossRefPubMedGoogle Scholar
  40. 40.
    Liu Y, Niu L, Zhang W, Cui L, Zhang X, Liang Y, et al. Effect of taurine on contractions of the porcine coronary artery. Pharmacol Rep. 2009;61:681–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Fanconi F, Giotti A, Manzini S, et al. The effect of taurine on high potassium- and noradrenaline-induced contraction in rabbit ear artery. Br J Pharmacol. 1982;75:605–12.CrossRefGoogle Scholar
  42. 42.
    Fujita T, Sato Y. The antihypertensive effect of taurine in DOCA-salt rats. J Hypertens Suppl. 1984;2:S563–5.CrossRefPubMedGoogle Scholar
  43. 43.
    Hano T, Kasano M, Tomari H, et al. Taurine suppresses pressor response through the inhibition of sympathetic nerve activity and the improvement in baro-reflex sensitivity of spontaneously hypertensive rats. Adv Exp Med Biol. 2009;643:57–63.CrossRefPubMedGoogle Scholar
  44. 44.
    Tian XY, Wong WT, Sayed N, Luo J, Tsang SY, Bian ZX, et al. NaHS relaxes rat cerebral artery in vitro via inhibition of l-type voltage-sensitive Ca2+ channel. Pharmacol Res. 2012;65:239–46.CrossRefPubMedGoogle Scholar
  45. 45.
    Li C, Cao L, Zeng Q, Liu X, Zhang Y, Dai T, et al. Taurine may prevent diabetic rats from developing cardiomyopathy also by downregulating angiotensin II type 2 receptor expression. Cardiovasc Drugs Ther. 2005;19:105–12.CrossRefPubMedGoogle Scholar
  46. 46.
    Jeevanandam M, Young DH, Ramias L, Schiller WR. Effect of major trauma on plasma free amino acid concentrations in geriatric patients. Am J Clin Nutr. 1990;51:1040–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care. 2000;3:417–24.CrossRefPubMedGoogle Scholar
  48. 48.
    Franconi F, Bennardini F, Mattana A, Miceli M, Ciuti M, Mian M, et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am J Clin Nutr. 1995;61:1115–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Henriksson J. Effect of exercise on amino acid concentrations in skeletal muscle and plasma. J Exp Biol. 1991;160:149–65.PubMedGoogle Scholar
  50. 50.
    Souza DB, Del Coso J, Casonatto J, et al. Acute effects of caffeine-containing energy drinks on physical performance: a systematic review and meta-analysis. Eur J Nutr. 2017;56:13–27.CrossRefPubMedGoogle Scholar
  51. 51.
    Waldron M, Patterson SD, Tallent J, Jeffries O. The effects of an oral taurine dose and supplementation period on endurance exercise performance in humans: a meta-analysis. Sports Med. 2018;48:1247–53.CrossRefPubMedGoogle Scholar
  52. 52.
    Waldron M, Knight F, Tallent J, Patterson S, Jeffries O. The effects of taurine on repeat sprint cycling after low or high cadence exhaustive exercise in females. Amino Acids. 2018;50:663–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Baum M, Weiss M. The influence of a taurine containing drink on cardiac parameters before and after exercise measured by echocardiography. Amino Acids. 2001;20:75–82.CrossRefPubMedGoogle Scholar
  54. 54.
    Galloway SD, Talanian JL, Shoveller AK, et al. Seven days of oral taurine supplementation does not increase muscle taurine content or alter substrate metabolism during prolonged exercise in humans. J Appl Physiol. 2008;105:643–51.CrossRefPubMedGoogle Scholar
  55. 55.
    Ong KL, Cheung BMY, Man YB, Lau CP, Lam KSL. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49:69–75.CrossRefPubMedGoogle Scholar
  56. 56.
    Nara Y, Zhao GS, Huang ZD, et al. Relationship between dietary factors and blood pressure in China. J Cardiovasc Pharmacol. 1990;16(Suppl. 8):S40–2.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Mark Waldron
    • 1
    • 2
  • Stephen David Patterson
    • 1
  • Jamie Tallent
    • 1
  • Owen Jeffries
    • 1
  1. 1.School of Health, Sport and Applied SciencesSt Mary’s UniversityLondonUK
  2. 2.School of Science and TechnologyUniversity of New EnglandArmidaleAustralia

Personalised recommendations